evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

341 questions · 354 findings · 26 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 58 · 16.4%GRADE not reported 4 · 1.1%Very low 51 · 14.4%Low 133 · 37.6%Moderate 82 · 23.2%High 26 · 7.3%

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Intervention not reported

Antibiotics prior to long‐term CVC insertion versus control: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…

The intervention showed no clear difference in antibiotics prior to long‐term CVC insertion versus control:… (moderate certainty).

1 finding from 1 review

Intervention not reported

Antibiotic versus heparin only lock/flush solution: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…

The intervention probably leads to lower antibiotic versus heparin only lock/flush solution: catheter‐related… (moderate certainty).

1 finding from 1 review

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

1 finding from 1 review